Shilpa Medicare Limited announced that it has received U.S. Food and Drug Administration approval for its ANDA, Imatinib Mesylate Tablets, 100 mg and 400 mg on January 17, 2019. Imatinib Mesylate Tablets is a generic equivalent of the reference listed drug (RLD), gleevec Tablets, 100 mg and 400 mg used in the treatment of leukemia as recommended and approved by FDA.